Women who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.
Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor size
After undergoing surgery, patients may be optimally or sub optimally debulked
Patients undergoing elective pancreatoduodenectomy (PD) for any diagnosis/indication
Hematologic parameters for patients undergoing biopsy only: patients should have international normalized ratio (INR) =< 1.4 and partial thromboplastin time (PTT) =< 40 seconds (unless due to lupus anticoagulant); in patients not meeting these parameters, clearance by hematology will be required prior to undergoing a biopsy
Patient capable of undergoing anesthesia
Eligible for otherwise curative treatment or undergoing concurrent therapy
Rochester patients: Willing to sign consent onto Evaluation of cardiac function in patients undergoing proton beam or photon radiotherapy, IRB number 15-007443
Hematologic parameters for patients undergoing biopsy only: patients should have international normalized ratio (INR) =< 1.4 and partial thromboplastin time (PTT) =< 40 seconds (unless due to lupus anticoagulant); in patients not meeting these parameters, clearance by hematology will be required prior to undergoing a biopsy
Patients undergoing primary medical treatment (hormone or chemotherapy) as initial treatment with neoadjuvant intent of reducing tumor size
Outpatients with MPE undergoing IPC placement
Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)
Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible.
Planned for multidisciplinary evaluation by a breast surgical oncologist and breast radiation oncologist. For patients undergoing mastectomy and desirous of reconstruction or those undergoing breast conservation in whom oncoplastic local tissue rearrangement or reduction mammoplasty is being considered, this multidisciplinary evaluation will also include a plastic surgeon
Any condition or history of illness or surgery that might pose an additional risk to men undergoing the VTP procedure;
Undergoing or have plans to undergo changes to current cancer treatment.
Patients who are currently undergoing other anti-tumor therapies or have concurrent active cancer
Patients must be willing to and medically capable of undergoing the surgical operation
Patients undergoing prior surgery or laser interstitial thermotherapy are allowed
Histologically confirmed prostate cancer of any stage undergoing RP
Patients undergoing an extrapleural pneumonectomy (EPP); lung sparing surgeries, such as pleurectomy/decortication, are acceptable
Hematologic parameters for patients undergoing biopsy only: patients should have international normalized ratio (INR) =< 1.4 and prothrombin time (PT) =< 40 seconds (unless due to lupus anticoagulant); in patients not meeting these parameters, clearance by hematology will be required prior to undergoing a biopsy
localized prostate cancer undergoing surveillance or surgery;
For patients undergoing definitive CFRT, patients with distant metastatic disease are not eligible
Patient undergoing yellow fever vaccination.
Patients with resectable primary NSCLC who are undergoing surgery to resect T3 to T4 lesions OR any patients with clinical NI or N2 disease regardless of T-stage
Patients can be undergoing concurrent systemic therapy, such as temozolomide, at the discretion of their treating oncologist
Patients undergoing preoperative chemoradiotherapy
Patients undergoing extrapleural pneumonectomy
Recent use of photosensitizing agents such as fluoroquinolones and retinoids or patients undergoing phototherapy.
Patients can be undergoing concurrent systemic therapy, such as temozolomide, at the discretion of their treating oncologist.
Undergoing autologous breast reconstruction
Undergoing delayed reconstruction
Subject is undergoing robotic partial nephrectomy being performed by participating surgeon
Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < 10/10 HLA allele matched allogeneic transplant are not eligible
Patients undergoing any other experimental intervention for oral mucositis
Part 1 patients must be undergoing repeat surgery that is clinically indicated as determined by their care providers
Patients undergoing pre-treatment secondary cytoreduction will undergo therapy with bevacizumab on cycle #2
Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy
Patients undergoing current treatments for other cancers
• Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity surgery;
Subject undergoing cardiothoracic surgery is not allergic to protamine; and
• Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure;
Subject is undergoing a neurologic surgical procedure;
Subject is undergoing a spinal surgical procedure;
Patients who are undergoing concomitant radiotherapy are NOT eligible for participation
Concurrent active malignancy under treatment except prostate or breast cancer undergoing treatment with hormonal therapy
Willing and capable of undergoing apheresis for collection of mononuclear cells
Undergoing laparoscopic or minimally invasive surgery
Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy
Patients who are undergoing concomitant radiotherapy are NOT eligible for participation
Same as above and patients undergoing single fraction spinal SBRT
Patients with uncontrolled hypertension (i.e., persistent grade 3 while undergoing treatment)
Undergoing concurrent neoadjuvant therapies for breast cancer
Patients undergoing either a Type II or III radical hysterectomy (Piver Classification)
Undergoing stapled anastomosis with the use of an experimental or non-FDA approved stapler.
Patients undergoing preoperative or adjuvant chemotherapy
Patients must have potentially resectable non-small cell lung cancer (NSCLC) by VATS as determined by a multidisciplinary team review; this primary should not have undergone any neoadjuvant chemotherapy (chemo-) or radiation therapy; only those patients undergoing surgery by conventional VATS will be included; (robotic procedures will not be eligible for inclusion in this study)
Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents including imiquimod, fluorouracil, ingenol mebutate (picato) to the selected treatment lesion sites
Active malignancy currently undergoing chemo or radiation therapy; hormone therapy is acceptable
Undergoing unilateral or bilateral, two-stage, tissue expander-assisted breast reconstruction
Patients must be undergoing repeat surgery that is clinically indicated as determined by their care providers
Patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs after chronic use
Women who are morbidly obese (BMI >= 40) undergoing laparotomy for any indication
Women undergoing panniculectomy at the time of laparotomy
Patients undergoing RC and IC formation in an elective setting for non-metastatic cancer
Undergoing treatment with surgery, chemotherapy, radiation, or combined modalities
Undergoing surgical procedures of expected length =< 6 hours requiring NMB
Undergoing lumpectomy (partial mastectomy) procedure
Are undergoing cancer treatment for another malignancy
Esophageal carcinoma, undergoing minimally invasive esophagectomy with intrathoracic anastomosis
Eligible patients must not be currently undergoing standard cytotoxic chemotherapy
Individuals who are actively undergoing standard cytotoxic chemotherapy
Undergoing radiation therapy or chemotherapy
Currently undergoing phase I complete decongestive therapy (CDT)
Undergoing primary resection of esophageal cancer and resultant esophagectomy
Patients undergoing reconstruction after mastectomy (either implant or tissue based)
INCLUSION - STUDY 1: Cancer adult patients undergoing neurotoxic chemotherapy (agents including platinums, vinca alkaloids, taxanes, proteasome inhibitors and interferons) will be eligible to participate
Patients undergoing penile prosthesis surgery
Undergoing pancreatic resection
Undergoing or initiating active surveillance
Patients undergoing gynecologic surgery via midline vertical laparotomy at University of Wisconsin Hospital and Clinics (UWHC)
Patients undergoing any resection requiring an anastomosis to the esophagus for palliative intent
Participant is undergoing chemotherapy
Patients undergoing diagnostic laparoscopy
Bladder cancer, undergoing radical cystectomy and ileal conduit diversion
Undergoing elective open radical cystectomy
Undergoing chemotherapy or radiation therapy at any time during the study
Undergoing an exploratory laparotomy for suspected gynecologic cancer, which includes metastatic disease from neoplasia originating in other organs
Patients undergoing anterior abdominal wall hernia repairs
Subjects with malignant dysphagia due to esophageal cancer or esophagogastric junction cancer who are undergoing upper endoscopic ultrasound or upper endoscopy for pre-treatment staging or symptom evaluation
Patients with BMI greater than or equal to 30 kg/m^2 who are undergoing hormonal treatment of endometrial cancer
Caregivers of patients undergoing HCT at Massachusetts General Hospital (MGH)
Caregivers of patients who are receiving hospice care will be excluded; caregivers who are themselves undergoing active cancer treatment will be excluded (hormonal treatment allowed)
Additionally, at time of enrollment, participants must be post-treatment (with the exception of adjuvant therapy) for their primary cancer and not actively undergoing treatment for a secondary, metastatic, or recurrence of cancer (local or distant)
Evaluation of Web-based Program: HNSCC patients who are currently undergoing or have recently completed radiation treatment (< 2 years)
Patients who have seen an oncologist after undergoing first line treatment imaging
The patient is undergoing Mohs surgery
Adult caregivers (> 18 years) of patients undergoing HSCT at MGH who agreed to participate in study
Patients undergoing concomitant colectomy
PILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Undergoing chemotherapy
Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment
All women, undergoing surgery, via a midline laparotomy
Undergoing chemotherapy or radiation
Patients with airway stents undergoing bronchoscopy
Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses)
Peer mentors will be past gynecologic cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease
Currently undergoing treatment for active gynecologic cancer
Outpatients with MPE undergoing IPC placement
Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)
Undergoing definitive treatment with either radiation alone or in combination with systemic therapy
undergoing a procedure other than laparotomy
Undergoing active treatment or in remission and undergoing active surveillance
Has active infectious disease undergoing systemic treatment excluding oral candidiasis
Actively undergoing any chemotherapy treatment at Maroone Cancer Center
Patients not actively undergoing chemotherapy at Maroone Cancer Center
Patients are undergoing other cancer treatments
Patients will be undergoing initial therapy for their disease or undergoing first salvage treatment, i.e. patients who fail therapy, or respond and relapse after initial therapy
Undergoing a procedure other than laparotomy
Any condition that would exclude women from undergoing regional anesthesia
Patients undergoing immediate tissue expander reconstruction following mastectomy by any of the surgeon co-investigators are eligible for the study
Patients undergoing skin-sparing mastectomy utilizing bioprosthetic mesh are eligible for the study
May include patients undergoing ileostomy or colostomy reversal
Patients who are undergoing colonoscopy for screening or surveillance purposes
Participants will be undergoing surgical excision to remove the ADH.
Patient must be asymptomatic for breast disease and undergoing routine screening
Patients are undergoing clinically indicated EGD
Patients are not undergoing clinically indicated EGD
Women actively undergoing in-vitro fertilization or fertility treatments are excluded
Undergoing salvage therapy
Patients undergoing other interventions to prevent CLABSI (e.g. Children's Oncology Group [COG] ACCL1034 with chromogranin [CHG], antimicrobial lock therapy, etc.) are ineligible
STUDY I: Smoked at least one cigarette per week prior to undergoing the CT scan
Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents including imiquimod, fluorouracil
Patients must be undergoing surgery that is clinically indicated as determined by their care providers
Women currently undergoing cancer treatment or with a known active cancer; history of malignancy is allowed as long as the patient has completed treatment > 3 months prior to enrollment
Patients undergoing esophageal resection
Not currently undergoing or planning to initiate chemotherapy
Patients undergoing cervicography OR colposcopy OR visual inspection with acetic acid (VIA) OR patients undergoing loop electrosurgical excision procedure (LEEP) for the treatment of cervical cancer
Patients undergoing a reduction mammoplasty OR
Undergoing colposcopy for the diagnosis of cervical cancer and LEEP or cervical biopsy for the treatment of premalignant cervical dysplasia
Patients with known or suspected pancreatic or ovarian carcinoma who will be undergoing clinically appropriate laparoscopic evaluation or treatment; patients will not undergo laparoscopy solely for the purpose of participation in this trial
Undergoing diagnostic breast MRI ordered by the referring clinician for staging and extent of disease
Participants must be undergoing a surgical procedure with the intention of removing more tissue than what would be taken for a biopsy
Men undergoing a first-time prostate biopsy driven by PSA elevation to rule out cancer
Anyone who would be normally excluded from undergoing an MRI examination as per Memorial Hospital for Cancer and Allied Diseases Screening Questionnaire
CHILD: Pediatrics patients aged 2-17 years undergoing myelosuppressive therapies for acute leukemias and other childhood cancers
Patients who would be normally excluded from undergoing an MRI examination as per Memorial Hospital for Cancer and Allied Disease Screening Questionnaire for MRI
Patients with unresectable HCC undergoing systemic therapy based on clinical indication or approved drug trial; and/or undergoing clinically indicated Y90 radioembolization
Is experiencing photo-toxicity or photo-sensitivity or is undergoing treatment for a photo-sensitive condition such as porphyria or lupus erythematosus;
Patients must be undergoing ovarian resection
Subjects undergoing MRI evaluation of the brain
Participants undergoing active treatment, or who have completed treatment, will have radiographic abnormalities that may or may not be recurrent tumor
Patients not undergoing radioembolization to the liver
Patients who have gynecologic malignancies involving the upper, middle and/or lower third of the vagina or are undergoing pelvic exenteration
Contraindication for undergoing EUS/FNA procedure (such as unwilling or medically unstable patients, patients with severe coagulopathy, patients with poor visualization on EUS for various reasons, etc)
Patients undergoing an upper endoscopy for BE surveillance with prior biopsy-confirmed BE with dysplasia (at least LGD).
Subject must be a patient undergoing diagnostic bronchoscopy and/or thoracoscopy at University of California Irvine Medical Center (UCIMC)
No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer
Undergoing salvage therapy
Patients undergoing bilateral neck dissection
Patients undergoing neck skin defect reconstruction
concurrent NSAID treatments while undergoing treatment
PATIENT: Undergoing treatment for cancer by one of the consented HCPs as per the HCP and/or EMR
Radiation oncology patients undergoing shorter courses of radiation or undergoing palliative courses of radiation
Men undergoing TRUS-guided prostate biopsy in the OR under anesthesia